Noroviruses (NoV) are the most common cause of acute gastroenteritis in the United States and Europe and are responsible for over 50% of all epidemic gastroenteritis worldwide. However, there is limited understanding of human NoV immunology, in part because of a lack of a cell-culture system. Therefore, we propose a study of the innate immune response to NoV using serum samples from experimental human NoV challenge studies. Preliminary studies suggest that individuals vary in their innate immune response to NoV, however little is known about the clinical implications of those differences. We hypothesize that differences in infection status, symptoms, viral titer, and duration of viral shedding in response to human NoV challenge result from increased pro-inflammatory cytokine production. Improved understanding of the mechanism of host defense will inform development of better prophylaxis (e.g. vaccines), predictive algorithms, and public health prevention strategies. The goal of this study is to elucidate differences in human innate immune response to NoV challenge. To address this goal, we propose: 1. To identify cytokines and chemokines predictive of infection status after NoV challenge and 2. To identify cytokines and chemokines predictive of symptoms, peak viral titer, and duration of viral shedding among infected volunteers. The fellowship applicant aspires to become an academic infectious disease physician, dividing her time between patient care and research. Her long-term goal is to use epidemiologic modeling in order to better understand infectious gastrointestinal disease pathogenesis in order to improve prevention and treatment efforts. Under this fellowship, she will acquire a rigorous methodological foundation in immunology and epidemiology through a combined MD and PhD in epidemiology. This training will be essential to address the proposed research question, develop skills necessary as an independent investigator, and achieve her long-term career goals. Specific goals for this fellowship include: 1. Developing expertise in epidemiologic modeling and techniques in human immunology, 2. Fostering high proficiency in experimental design, 3. Establishing a strong foundation in clinical medicine, 4. Gaining exposure to a variety of clinical disciplines and ongoing population studies, 5. Maintaining an active understanding of trends and developments in human immunology, epidemiology, and clinical medicine, 6. Building excellence in scientific writing and oral presentations, and 7. Actively pursuing career development opportunities. At the start of the funding period, the applicant will have already completed two years of medical studies at Emory University School of Medicine and one year of study in the Epidemiology doctoral program. The proposed research seeks to understand the immunologic basis of NoV infection in humans and to identify clinically-relevant biochemical predictors of infection status, symptoms, viral titer, and duration of viral shedding. Understanding the innate immune response is critical for advancing the development of NoV therapeutics, creating surveillance tools, and predicting clinical outcomes.

Public Health Relevance

Noroviruses (NoV) are the most common cause of acute gastroenteritis worldwide. The goal of this study is to understand how the human innate immune response to NoV predicts 1) whether or not an individual becomes infected;and 2) symptoms and viral shedding levels within infected individuals. Our work will provide an understanding of the innate immune response to this common infection and lay the groundwork for developing improved vaccines, surveillance, and predictive algorithms for NoV illness.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Individual Predoctoral NRSA for M.D./Ph.D. Fellowships (ADAMHA) (F30)
Project #
1F30DK100097-01
Application #
8594805
Study Section
Special Emphasis Panel (ZDK1-GRB-2 (M1))
Program Officer
Podskalny, Judith M,
Project Start
2013-09-12
Project End
2018-09-11
Budget Start
2013-09-12
Budget End
2014-09-11
Support Year
1
Fiscal Year
2013
Total Cost
$47,232
Indirect Cost
Name
Emory University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
066469933
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Newman, Kira L; Lynch, Raymond J; Adams, Andrew B et al. (2017) Hospitalization Among Individuals Waitlisted For Kidney Transplant. Transplantation 101:2913-2923
Newman, K L; Moe, C L; Kirby, A E et al. (2016) Norovirus in symptomatic and asymptomatic individuals: cytokines and viral shedding. Clin Exp Immunol 184:347-57
Newman, Kira L; Fedewa, Stacey A; Jacobson, Melanie H et al. (2016) Racial/Ethnic Differences in the Association Between Hospitalization and Kidney Transplantation Among Waitlisted End-Stage Renal Disease Patients. Transplantation 100:2735-2745
Tauxe, William M; Haydek, John P; Rebolledo, Paulina A et al. (2016) Fecal microbiota transplant for Clostridium difficile infection in older adults. Therap Adv Gastroenterol 9:273-81
Newman, Kira L; Leon, Juan S; Newman, Lee S (2015) Estimating Occupational Illness, Injury, and Mortality in Food Production in the United States: A Farm-to-Table Analysis. J Occup Environ Med 57:718-25
Newman, Kira L; Varkey, Jay; Rykowski, Justin et al. (2015) Yelp for Prescribers: A Quasi-Experimental Study of Providing Antibiotic Cost Data and Prescription of High-Cost Antibiotics in an Academic and Tertiary Care Hospital. J Gen Intern Med 30:1140-6
Newman, Kira L; Leon, Juan S (2015) Norovirus immunology: Of mice and mechanisms. Eur J Immunol 45:2742-57
Newman, K L; Leon, J S; Rebolledo, P A et al. (2015) The impact of socioeconomic status on foodborne illness in high-income countries: a systematic review. Epidemiol Infect 143:2473-85
Newman, K L; Moe, C L; Kirby, A E et al. (2015) Human norovirus infection and the acute serum cytokine response. Clin Exp Immunol 182:195-203
Newman, Kira L; Marsh, Zachary; Kirby, Amy E et al. (2015) Immunocompetent adults from human norovirus challenge studies do not exhibit norovirus viremia. J Virol 89:6968-9